Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Quadrivalent Market From 2025 to 2029?

The quadrivalent industry has seen robust growth over the past few years. It is projected to surge from $8.87 billion in 2024 to $9.51 billion in 2025, marking a compound annual growth rate (CAGR) of 7.2%. Factors such as disease complexity, education programs, historical health scenarios, healthcare development and advancements in technology have contributed to the growth witnessed in the past period.

The size of the Quadrivalent market is anticipated to significantly expand in the ensuing years, with expectations to reach “$13.91 billion in 2029,” demonstrating a compound annual growth rate (CAGR) of “10.0%”. Factors contributing to this projected growth during the forecast period include global health incidents, competitive movements, educational initiatives, regulatory alterations, and changing patterns in disease spread. Key trends expected during the forecast period encompass disease ubiquity, the regulatory climate, healthcare facilities, customer awareness and learning, and the competitive scenario.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9335&type=smp

What Elements Are Contributing To Growth In The Quadrivalent Market?

The quadrivalent market is anticipated to expand due to the increasing occurrence of chronic and infectious diseases. Chronic ailments are long-term illnesses induced by genetics and lifestyle, whereas infectious illnesses are those resulting from infectious agents like viruses, bacteria, fungi, or protozoa. Quadrivalent vaccines play an essential role in preventing severe infections and diseases unrelated to the specific infections they target, reducing both morbidity and mortality rates. Quadrivalent vaccines are utilized for preventing chronic (non-communicable) diseases linked to infectious agents in carcinogenesis process. As per a report in September 2024 by the Centers for Disease Control and Prevention, a non-profit organization based in the US, in week 37, 0.5% of samples tested positive for flu, with an 8.7% overall positivity rate since October 1, 2023 (Week 40). Out of all positives, 91.4% represented influenza A and 8.6% influenza B during week 37, while overall, 69.2% were influenza A and 30.8% were influenza B. This signifies a progressive increase in the positivity rate and a greater proportion of influenza B cases over time. Consequently, the quadrivalent market growth is driven by the escalating prevalence of chronic and infectious diseases.

Which Segments Are Detailed In The Global Quadrivalent Market Report?

The quadrivalent market covered in this report is segmented –

1) By Type: Intradermal Shot, Intramuscular Injection, Nasal Spray

2) By Technology: Conjugated, Live, Inactivated, Recombinant, Toxoid, Other Technologies

3) By Disease: Cancer, Hepatitis, Pneumococcal Disease, COVID-19, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus, Other Diseases

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospital And Pharmacy, Government Suppliers, Other Channels (NGOs)

Subsegments:

1) By Intradermal Shot: Standard Intradermal Injection, Needle-Free Intradermal Delivery

2) By Intramuscular Injection: Standard Intramuscular Injection, Adjuvanted Intramuscular Injection

3) By Nasal Spray: Live Attenuated Nasal Spray, Inactivated Nasal Spray

Which Emerging Trends And Strategic Shifts Are Shaping The Quadrivalent Market?

The growing trend of product innovations is becoming increasingly popular in the quadrivalent market. The principal companies in this industry are focusing their efforts on creating novel solutions in order to solidify their standing in the market. As an example, in September 2022, AstraZeneca, a pharmaceutical corporation based in the UK, rolled out FluMist quadrivalent (Influenza Vaccination Live, Intranasal). This is a flu vaccine administered through a needle-free nasal spray, which has received approval from the Food and Drug Administration (FDA) for individuals aged 2 to 49. This live attenuated influenza vaccine (LAIV) comes in trivalent or quadrivalent variations and is covered under most health insurance policies as well as the vaccines for children scheme.

Who Are The Key Contributors To Growth In The Quadrivalent Market?

Major companies operating in the quadrivalent market include AstraZeneca Plc, Serum Institute of India Private Limited, Sanofi S.A., GlaxoSmithKline Plc, CSL Limited, Bharat Biotech International Limited, Hualan Biological Engineering Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Pfizer Inc., Bio Med Pvt. Ltd., Walvax Biotechnology Co. Ltd., Chongqing Zhifei Biological Products Co. Ltd., Emergent BioSolutions Inc., Biological E. Limited, GSK Biologicals SA, Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products Co. Ltd., Beijing Tian Tan Biological Products Co. Ltd., Shanghai Zhijiang Bio-pharm Co. Ltd., Bio Farma, Butantan Institute, Pasteur Institute of India, China National Biotec Group Co. Ltd. (CNBG)

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/quadrivalent-global-market-report

Which Region Is Projected To Lead The Quadrivalent Market By 2025?

North America was the largest region in the quadrivalent market in 2024. The regions covered in the quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9335&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model